probucol has been researched along with Carcinoma, Hepatocellular in 5 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol did not increase human SR-BI protein in the liver of transgenic mice carrying the entire human SR-BI genome." | 1.33 | Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. ( Hirano, K; Ikegami, C; Koseki, M; Maruyama, T; Masuda, D; Matsuura, F; Nakagawa-Toyama, Y; Shimomura, I; Tsujii, K; Ueda, Y; Yamashita, S; Zhang, Z, 2005) |
| "In Fu5AH hepatoma cells that contain scavenger receptor class B, type I, but not functional ABCA1, we observed no effect of probucol on cholesterol efflux." | 1.32 | Probucol inhibits ABCA1-mediated cellular lipid efflux. ( Bernini, F; Favari, E; Ronda, N; Rothblat, GH; Zanotti, I; Zimetti, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jendralla, H | 1 |
| Granzer, E | 1 |
| von Kerekjarto, B | 1 |
| Krause, R | 1 |
| Schacht, U | 1 |
| Baader, E | 1 |
| Bartmann, W | 1 |
| Beck, G | 1 |
| Bergmann, A | 1 |
| Kesseler, K | 1 |
| Favari, E | 1 |
| Zanotti, I | 1 |
| Zimetti, F | 1 |
| Ronda, N | 1 |
| Bernini, F | 1 |
| Rothblat, GH | 1 |
| Hirano, K | 1 |
| Ikegami, C | 1 |
| Tsujii, K | 1 |
| Zhang, Z | 1 |
| Matsuura, F | 1 |
| Nakagawa-Toyama, Y | 1 |
| Koseki, M | 1 |
| Masuda, D | 1 |
| Maruyama, T | 1 |
| Shimomura, I | 1 |
| Ueda, Y | 1 |
| Yamashita, S | 1 |
| McLean, LR | 1 |
| Brake, N | 1 |
| Hagaman, KA | 1 |
| Pfeuffer, MA | 1 |
| Richard, BM | 1 |
| Pittman, RC | 1 |
5 other studies available for probucol and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Topics: Animals; Anticholesteremic Agents; Caproates; Carcinoma, Hepatocellular; Cholesterol; Dogs; Humans; | 1991 |
Probucol inhibits ABCA1-mediated cellular lipid efflux.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Carcinoma, Hepatocel | 2004 |
Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.
Topics: Adult; Animals; Anticholesteremic Agents; Atherosclerosis; Carcinoma, Hepatocellular; Cell Line, Tum | 2005 |
Interactions of MDL 29,311 and probucol metabolites with cholesteryl esters.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol Esters; Crystallization; Drug Interactions; Probucol | 1994 |
Probucol increases the selective uptake of HDL cholesterol esters by Hep G2 human hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cell Membrane; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Do | 1992 |